| Literature DB >> 17353346 |
Cary Hsu1, Stephanie A Jones, Cyrille J Cohen, Zhili Zheng, Keith Kerstann, Juhua Zhou, Paul F Robbins, Peter D Peng, Xinglei Shen, Theotonius J Gomes, Cynthia E Dunbar, David J Munroe, Claudia Stewart, Kenneth Cornetta, Danny Wangsa, Thomas Ried, Steven A Rosenberg, Richard A Morgan.
Abstract
Malignancies arising from retrovirally transduced hematopoietic stem cells have been reported in animal models and human gene therapy trials. Whether mature lymphocytes are susceptible to insertional mutagenesis is unknown. We have characterized a primary human CD8(+) T-cell clone, which exhibited logarithmic ex vivo growth in the absence of exogenous cytokine support for more than 1 year after transduction with a murine leukemia virus-based vector encoding the T-cell growth factor IL-15. Phenotypically, the clone was CD28(-), CD45RA(-), CD45RO(+), and CD62L(-), a profile consistent with effector memory T lymphocytes. After gene transfer with tumor-antigen-specific T-cell receptors, the clone secreted IFN-gamma upon encountering tumor targets, providing further evidence that they derived from mature lymphocytes. Gene-expression analyses revealed no evidence of insertional activation of genes flanking the retroviral insertion sites. The clone exhibited constitutive telomerase activity, and the presence of autocrine loop was suggested by impaired cell proliferation following knockdown of IL-15R alpha expression. The generation of this cell line suggests that nonphysiologic expression of IL-15 can result in the long-term in vitro growth of mature human T lymphocytes. The cytokine-independent growth of this line was a rare event that has not been observed in other IL-15 vector transduction experiments or with any other integrating vector system. It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17353346 PMCID: PMC1890824 DOI: 10.1182/blood-2006-06-029173
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113